Atopic dermatitis (eczema) is a long-term inflammatory skin condition that causes itching, redness, and flare-ups that can make daily life difficult. It often begins in childhood but can occur at any age.
Many people continue to experience uncontrolled symptoms even with available medicines, as well as side effects.
This study is evaluating a new investigational medicine that may help treat atopic dermatitis symptoms in adults with moderate to severe atopic dermatitis.
The investigational medicine is designed to target a specific immune pathway that helps the body’s own cells control inflammation. By supporting this natural immune balance, the medicine may help reduce flare-ups, calm inflammation, and support skin healing without broadly suppressing the immune system.
The study will test how safe and well-tolerated the investigational medicine is and whether it can treat skin health and overall symptoms in people living with atopic dermatitis.
You may be eligible if:
If eligible, you will take part in the study for approximately 9 months, including screening, treatment, optional crossover treatment and follow-up.
The study involves 16 clinic visits, including 8 fasting visits, and regular health and skin assessments throughout the treatment and follow-up periods.
Participants will attend regular clinic visits throughout screening, treatment, optional crossover treatment and follow-up periods, including several fasting visits and ongoing skin and health assessments.
Participants will receive subcutaneous, under the skin, injections of either the investigational medicine or placebo once every four weeks during the initial 12-week treatment period. Participants who consent will receive additional treatment as part of the study.
During the study, participants will undergo comprehensive health and skin assessments, including:
These assessments will help the study team monitor safety, treatment response, and changes in skin health over time.
Reimbursement for study-related time and travel will be provided.